Clinical Trial Update: Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab/vibostolimab coformulation (MK-7684A), with or without docetaxel, versus docetaxel alone in metastatic non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Taxotere (docetaxel)
• Vibostolimab (vibostolimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-04-02